# A coordinated FLASH radiotherapy evidence programme with shared dose-rate standards

Source: https://onco.cc/ideas/idea-fund-flash-evidence-programme/  
OnCo record `idea-fund-flash-evidence-programme` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ultra-fast radiotherapy may spare healthy tissue while still killing tumours, but every centre is testing it differently. A coordinated programme would agree the measurements and run the trials that settle whether it works.

## Summary

FLASH radiotherapy (dose delivered in under a second at ultra-high dose rate) shows a normal-tissue sparing effect in animals; the first human trial (FAST-01, proton FLASH for bone metastases) showed feasibility. Evidence is fragmented across manufacturers and centres with different beam types (electron, proton, photon prototypes), dose-rate definitions and dosimetry. The programme would fund a consortium to standardise dosimetry and dose-rate reporting, build a shared preclinical platform to define the biological conditions of the effect, and run coordinated multi-centre phase 2 and randomised trials in indications where normal-tissue toxicity limits cure (head and neck, thoracic, paediatric). Without coordination the field risks a decade of unconvincing small studies.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A coordinated programme produces, within six years, a randomised trial demonstrating whether FLASH reduces a pre-specified grade 3 or higher toxicity endpoint by at least a third at equal tumour control in a curative indication, settling the clinical question one way or the other.
- Rationale: Preclinical FLASH sparing has been reproduced across species and tissues, but the mechanism and required beam parameters are debated; the history of proton therapy shows that letting technology diffuse before randomised evidence produces decades of unresolved argument. Coordinated dosimetry standards were what made IMRT and SBRT trials interpretable.
- Proposed test: Fund the consortium with mandatory shared dosimetry, complete a multi-centre phase 2 in one indication within three years, and launch a randomised trial with a toxicity primary endpoint.
- Maturity: early-clinical
- Actor: research

## Sources

- FAST-01 (NCT04592887): https://clinicaltrials.gov/study/NCT04592887

## Connected records

- ideas: [A regulatory pathway for new radiotherapy techniques modelled on drug development](https://onco.cc/ideas/idea-fund-radiotherapy-innovation-pathway/), [Core-funded radiotherapy trials infrastructure with central quality assurance](https://onco.cc/ideas/idea-fund-radiotherapy-trials-infrastructure/), [Pooled coverage-with-evidence for proton therapy across all centres](https://onco.cc/ideas/idea-fund-proton-coverage-with-evidence/)
- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [FLASH radiotherapy](https://onco.cc/technologies/flash-rt/), [Proton therapy](https://onco.cc/technologies/proton-therapy/)
- companies: [IBA (Ion Beam Applications)](https://onco.cc/companies/iba/), [Varian (Siemens Healthineers)](https://onco.cc/companies/varian/)
- bottlenecks: [Surgery and radiotherapy cure most, get least](https://onco.cc/bottlenecks/b-surgery-radiation-innovation/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-flash-evidence-programme.json